Survey results indicate children gain more responsibility through sublingual immunotherapy treatment.
iPUMP® served to help thousands of patients who suffer from allergies maintain their prescribed treatment therapy. A fresh research study demonstrated that the connected device increased SLIT user adherence levels by 15%.
What’s driving the change?
Analysis from the SPEED survey emerged from Aptar Digital Health and Stallergenes Greer who operate as major digital allergy care companies. The study revealed positive results among 5 to 12 year old children who used iPUMP® in terms of their self-directed allergy treatment process. In just three months:
- Parental help dropped from 50% to 28%.
- Child self-administration jumped from 24% to 58%.
- A majority of 90% of parents experienced calmness thanks to the digital tool.
A properly designed support platform demonstrates its ability to transform patients from followers to independent contributors.
What is iPUMP®?
Medical science created the digital assistance tool known as iPUMP® specifically for sublingual immunotherapy. It’s designed to help patients:
- Follow the right dose
- Stay consistent
- Track their progress
Users can view their custom treatment plan through a mobile phone application which integrates with this device. This French healthcare system launched during the early months of 2023 and accumulated more than 9000 patient users.
Why this matters
The effects of allergy treatment become diminished every time patients decide to skip their medications. The SPEED survey demonstrates how iPUMP® enables patients to stay properly on track with their treatment. Better outcomes come from increased patient engagement and this presents particular benefit to children who need to manage their chronic illnesses.
Key insights from SPEED
The survey covered over 180 patients. The evaluation of treatment modifications took place during the third month period using iPUMP®.
- Stronger daily habits
- More confident parents
- Better overall control of sublingual immunotherapy
According to Aptar Digital Health’s Marcus Bates such tools represent the emerging technological solutions. Better outcomes for patients develop as the technology enables them to maintain proper health behaviors.
What’s next for iPUMP®?
Broad implementation of this technology seems more probable because of its extraordinary outcome data. Sublingual immunotherapy therapy should expand its accessibility and efficiency to families throughout Europe as well as other regions globally.
Aptar Digital Health together with Stallergenes Greer continuously develops solutions that benefit patients and doctors to improve the accuracy and reliability of allergy treatments.
